Plus Therapeutics
PSTV
3 hedge funds and large institutions have $35.4M invested in Plus Therapeutics in 2013 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
6% more capital invested
Capital invested by funds: $33.4M → $35.4M (+$2.02M)
0% more funds holding
Funds holding: 3 → 3 (0)
65% less call options, than puts
Call options by funds: $178K | Put options by funds: $511K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$847K |
| 2 |
D.E. Shaw & Co
New York
|
-$295K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$175K |
| 4 |
ProShare Advisors
Bethesda,
Maryland
|
-$148K |
| 5 |
AC
Amici Capital
New York
|
-$70K |
PSTV Hedge Fund Activity: Q4 2013 in Review
3 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q4 2013, worth a combined $35.4M — up 6.1% from $33.4M a quarter earlier.
Fund positioning in PSTV was balanced in Q4 2013: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Jennison Associates, cutting an estimated $847K.
- 3 institutional investors held Plus Therapeutics (PSTV) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $35.4M of Plus Therapeutics stock for Q4 2013, up 6.1% quarter-over-quarter.
- 0 funds opened new Plus Therapeutics positions in Q4 2013 and 0 closed out.
- The largest Plus Therapeutics seller in Q4 2013 was Jennison Associates, an estimated $847K sold.
Based on aggregated 13F filings for Q4 2013.